New federal regulations allow HIV-positive individuals to be live kidney donors; however, potential candidacy for donation is poorly understood given the increased risk of end-stage renal disease (ESRD) associated with HIV infection. To better understand this risk, we compared the incidence of ESRD among 41 968 HIV-positive participants of North America AIDS Cohort Collaboration on Research and Design followed for a median of 5 years with the incidence of ESRD among comparable HIV-negative participants of National Health and Nutrition Examination III followed for a median of 14 years. We used risk associations from multivariable Cox proportional hazards regression to derive cumulative incidence estimates for selected HIV-positive scenarios (no history of diabetes, hypertension, AIDS, or hepatitis C virus coinfection) and compared these estimates with those from similarly selected HIV-negative scenarios. For 40-year-old HIV-positive individuals with health characteristics that were similar to those of age-matched kidney donors, viral load <400 copies/ mL, and CD4
+ count ≥500 cells/lL, the 9-year cumulative incidence of ESRD was higher than that of their HIV-negative peers, yet still low: 2.5 versus 1.1 per 10 000 among white women, 3.0 versus 1.3 per 10 000 among white men, 13.2 versus 3.6 per 10 000 among black women, and 15.8 versus 4.4 per 10 000 among black men. HIV-positive individuals with no comorbidities and well-controlled disease may be considered low-risk kidney donor candidates.
Introduction
The Human Immunodeficiency Virus Organ Policy Equity Act of 2013 ended the ban on HIV-positive-to-HIV-positive transplantation (1) . For HIV-positive transplant candidates on the deceased donor waiting list, the pool of available organs may thus increase by 500-600 per year (2), the time from listing to transplantation may decrease significantly, and the benefits of transplantation may be realized sooner (3, 4) . However, for HIV-positive transplant candidates who wish to consider HIV-positive live kidney donor transplantation, concerns about the long-term risks to the HIV-positive kidney donor may be a drawback (5) .
An important risk associated with live kidney donation is end-stage renal disease (ESRD) (6) (7) (8) (9) (10) (11) (12) (13) . HIV-positive individuals may be considered to be too high risk for donor nephrectomy because they have an increased risk of ESRD compared with their HIV-negative counterparts, especially in the presence of common risk factors such as diabetes and hypertension (14) (15) (16) (17) (18) (19) . However, the additional risk of ESRD among HIV-positive individuals who meet standard kidney donor eligibility criteria (20) (21) (22) and who meet the Department of Health and Human Services definition of well-controlled HIV infection (CD4 + T cell count >500/lL for the 6-month period before donation, HIV-1 RNA <50 copies/mL, no evidence of invasive opportunistic complications of HIV infection) (5) is unknown.
To evaluate the additional risk of ESRD in HIV-positive potential live kidney donors, we estimated the cumulative incidence of ESRD for various low-risk clinical scenarios based on age, race, renal function, HIV viral load, and CD4 + count. We then compared these cumulative incidence estimates with similar clinical scenarios in an HIV-negative population.
Methods

Data source: HIV-positive potential donors
HIV-positive potential donors were drawn from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). NA-ACCORD is a consortium of clinical and interval HIV cohorts from Canada and the United States (23) . It is one of seven regional collaborations of the International Epidemiologic Databases to Evaluate AIDS supported by the National Institutes of Health and draws participants from more than 100 clinical sites that represent HIV-positive individuals engaged in clinical care (23, 24) . Each contributing cohort uses standardized cohort-specific methods of data collection. At scheduled intervals, cohorts securely transfer demographic, medication, laboratory, diagnosis, and vital status information to the NA-ACCORD central Data Management Core (University of Washington), where data undergo quality control for completeness and accuracy before they are combined into harmonized data files. The data are subsequently sent to the Epidemiology/Biostatistics Core (Johns Hopkins University), where they undergo additional quality control and assembly into analytic data files. The human subject activities of the NA-ACCORD and each participating cohort study have been reviewed and approved by their corresponding local institutional review boards. Eleven clinic-based cohorts (nine in the United States and two in Canada; n = 41 968) within the NA-ACCORD used medical record evidence of arteriovenous fistula placement, dialysis, and kidney transplantation to validate cases of ESRD in clinical care between January 2000 and December 2009 (25) . The study end point was defined as the earliest one of the following events (date of ESRD diagnosis, date of death, date of cohort administrative censorship, or December 31, 2009).
Data source: HIV-negative potential donors
Healthy HIV-negative individuals were drawn from the Third National Health and Nutrition Examination Survey (NHANES III) (n = 16 025) (26) . In this survey medical information was obtained from patient self-report, physical examination, and radiologic and laboratory test results at NHANES III enrollment between 1988 and 1994. ESRD outcomes were ascertained by linkage to the Centers for Medicare & Medicaid Services's medical evidence Form 2728 (certification of ESRD) and to the centers' patient profile and death notification Form 2746 (including records through September 30, 2008 ), as we have previously reported (10) . ESRD was defined as the initiation of maintenance dialysis or receipt of a kidney transplant, whichever was identified first.
Cumulative incidence of ESRD
We evaluated the associations between the risk of ESRD and various demographic and clinical characteristics for the HIV-positive cohort (NA-ACCORD) and the HIV-negative cohort (NHANES III). To ensure model stability (i.e. a sufficient number of events for multivariable regression), we included individuals with diabetes mellitus, hypertension, and estimated glomerular filtration rate (eGFR) of 45-90 mL/min/1.73 m 2 (27) For both cohorts, a base-case scenario was defined to reflect the average kidney donor in the United States: an SBP of 120 mm Hg, a urinary albumin:creatinine ratio of 4 mg/g, no history of smoking, no diabetes, and no hypertension (10) . For the HIV-positive cohort, a low-risk scenario was defined to reflect the average kidney donor characteristics as well as the Department of Health and Human Services criteria for well-controlled HIV infection: CD4 + T cell count >500/lL for the 6-month period before donation, HIV-1 RNA of <50 copies/mL, and no evidence of invasive opportunistic complications of HIV infection (5) . The linear function for each participant was centered on that of the base-case scenario within each category of age, race, and sex. All reported cumulative incidence estimates were derived from the following expression:
where h 0 (t) is the nonparametric hazard for the base-case; exp(Xb) is the maximum-likelihood estimate of the difference (on a log scale) between the hazard for the base-case and the hazard for the specific clinical scenario with explanatory variables X; and t is the number of years of follow-up (t = 9 for all reported analyses). In other words, Cox regression on a vector of explanatory variables, X, yielded a vector of log hazard ratios, b. The baseline survival function was subsequently obtained by applying the value of zero to all explanatory variables in the mathematical expression depicted here. To obtain the survival function for a given scenario, we specified the difference in value (e.g. 5 years) between the scenario (i.e. 45 years) and the base-case (40 years). To evaluate the Cox proportional hazards assumption, we used the global test developed by Therneau and Grambsch, which is equivalent to testing for a nonzero slope in a generalized linear regression of the scaled Schoenfeld residuals on functions of time. For our study, the global test suggested proportional hazards (p = 0.4).
Statistical analysis
We compared the 9-year cumulative incidence of ESRD in HIV-positive potential donors with HIV-negative potential donors. The difference in cumulative incidence between HIV-positive potential donors and HIVnegative potential donors was reported as the risk increase associated with HIV infection. All analyses were performed using Stata 14.0/MP for Linux (Stata Corp, College Station, TX). All hypothesis tests were twosided (a = .05).
Results
Study population
The median age of the HIV-positive cohort was 41 years; 40% were black and 15% were Hispanic; 78% were male; and 2% had diabetes and 15% had hypertension. The median eGFR was 104 mL/min/ 1.73 m 2 , median SBP was 125 mm Hg, and median BMI was 25 kg/m 2 . In addition, 74% reported having ever smoked cigarettes, and 19% were hepatitis C virus (HCV) coinfected. By HIV transmission risk group, 45% were men who have sex with men, 33% were heterosexual, 11% were current injection drug users or had a history of injection drug use, and 12% were in other categories. At study entry, median viral load was 926 copies/mL, 47% had initiated ART, 43% had suppressed HIV viral load (<400 copies/mL), 32% had a CD4 + count of >500 cells/lL, and 20% had AIDS. The median age of the HIV-negative cohort was 42 years. Compared with the HIV-positive cohort, the HIV-negative cohort had a lower proportion of black (28%) and male (47%) participants but a higher prevalence of participants with diabetes (12%) and hypertension (26%). The median albumin:creatinine ratio was 6 mg/g, median eGFR was 103 mL/min/1.73 m 2 , median SBP was 122 mm Hg, and median BMI was 26 kg/m 2 . There were 49% who reported ever smoking cigarettes, and 2% were HCV seropositive ( Table 1) .
Risk of ESRD
In the HIV-positive cohort, there were 126 ESRD events during a period of 212 804 person-years of follow-up; the median follow-up was 5 years (interquartile range, 3-8 years). In the HIV-negative cohort, there were 114 ESRD events during a period of 205 616 person-years of followup; the median follow-up was 14 years (IQR, 12-15). The HIV-negative cohort has no meaningful values for HIV transmission risk group, use of antiretroviral therapy, HIV viral load, CD4 + count, and history of AIDS; the entire HIV-positive cohort has no data on urinary albumin:creatinine ratio; >50% of the cohort has missing values for systolic blood pressure (NA, not available for the HIV-positive cohort; not applicable to the HIV-negative cohort). 2 Records on smoking were available for only 43% of the HIVpositive cohort, were imputed for an additional 16% of the cohort, and were left missing for 41% of the cohort. Table 2 shows the associations between the risk of ESRD and the demographic and clinical characteristics of both cohorts at baseline. In the HIV-positive cohort, the highest risks were observed among black individuals and those with diabetes, hypertension, a low eGFR, a history of smoking, HCV coinfection, a high viral load, a low CD4 count, a history of AIDS, and longer duration of exposure to ART (but only among those with <9 years of previous exposure to ART). In the HIV-negative cohort, the highest risks were observed among black individuals and those with diabetes, a low eGFR, a high urinary albumin:creatinine ratio, a high SBP, a history of smoking, and HCVpositive serology. Hypertension was not associated with risk of ESRD in this cohort; however, an association was observed in a sensitivity analysis that excluded urinary albumin:creatinine ratio and SBP.
An inverse association was observed between age and risk of ESRD in both the HIV-positive and HIV-negative cohorts; however, this effect was not observed among those <50 years old in the HIV-negative cohort (p < 0.001 for interaction term for age <50 years and HIV status; p = 0.4 for interaction term for age >50 years and HIV status). Similarly, an inverse association was observed between eGFR and risk of ESRD in both the HIV-positive and HIV-negative cohorts; however, this effect was not observed among those with an eGFR of >90 mL/min/1.73 m Black individuals had an increased risk of ESRD compared with white individuals; however, this increase in risk was greater than twofold higher in the HIV-positive cohort compared with the HIV-negative cohort (p = 0.03 for interaction of black race and HIV status in a joint HIVpositive and HIV-negative cohort model that excluded urinary albumin:creatinine ratio and SBP).
Cumulative incidence of ESRD The 9-year cumulative incidence of ESRD varied by orders of magnitude from low-risk scenarios (e.g. three ESRD events per 10 000 for a 40-year-old HIV-positive white man with no history of diabetes, no hypertension, eGFR of 95 mL/min/1.73 m 2 , no HCV coinfection, using ART [including TDF] for 1 year, with suppressed viral load, CD4 + count of >500 cells/lL, and no history of AIDS) to high-risk/base-case scenarios (e.g. 115 ESRD events per 10 000 for a 40-year-old HIV-positive black man with no history of diabetes, no hypertension, eGFR of 105 mL/min/1.73 m 2 , no HCV coinfection, and using ART, but with a viral load of 100 000 copies/mL and CD4 + count of 200 cells/lL) (Figure 1 ).
Risk increase associated with HIV infection
The 9-year cumulative incidence of ESRD varied considerably by baseline eGFR. For the base-case of a 40-year-old patient, the 9-year cumulative incidence of ESRD in the HIV-positive and HIV-negative cohorts was 2.5 versus 1.1 per 10 000 among white women, 3.0 versus 1.3 per 10 000 among white men, 13.2 versus 3.6 per 10 000 among black women, and 15.8 versus 4.4 per 10 000 among black men (Figure 2 ). For the base case of a 50-year-old patient, the 9-year cumulative incidence of ESRD in the HIV-positive and HIVnegative cohorts was 1.5 versus 1.4 per 10 000 among white women, 1.8 versus 1.6 per 10 000 among white men, 8.0 versus 4.6 per 10 000 among black women, and 9.5 versus 5.5 per 10 000 among black men. In contrast, for the base case of a 30-year-old patient, the 9-year cumulative incidence of ESRD in the HIV-positive and HIV-negative cohorts was 3.6 versus 0.9 per 10 000 among white women, 4.3 versus 1.0 per 10 000 among white men, 19.3 versus 2.9 per 10 000 among black women, and 23.0 versus 3.5 per 10 000 among black men. The risk increase associated with HIV varied substantially by baseline clinical characteristics and was lowest for older white individuals older than 40 years and highest for young black individuals younger than 40 years (Table 3) .
Discussion
In this North American cohort study of HIV-positive individuals, the 9-year risk of ESRD varied by orders of magnitude across various clinical scenarios. However, in subgroups with no comorbidities and well-controlled HIV infection, the risk increase associated with HIV for the base case of a 40-year-old patient was 1 per 10 000 among white women, 2 per 10 000 among white men, 10 per 10 000 among black women, and 11 per 10 000 among black men. For perspective, these estimates (particularly those for white individuals) are comparable to the risk increase in HIV-negative potential donors associated with cigarette smoking (12), which is not a contraindication to kidney donation (one per 10 000 among white women, one per 10 000 among white men, three per 10 000 among black women, and four per 10 000 among black men) (20) (21) (22) .
HIV infection may thus be viewed as a relative contraindication to kidney donation because carefully selected HIV-positive donor candidates may have an acceptable risk of ESRD, comparable to the 1.8-fold increase in risk observed among smokers in this study and in the recent report by Grams et al (12) . In contrast, risk factors that are traditionally viewed as absolute contraindications to kidney donation are associated with substantially higher risks compared with smoking: 5.2-fold increase in risk associated with diabetes, 3.4-fold increase in risk per 20-mm Hg increase in SBP ≥120 mm Hg, and 4.0-fold increase in risk per 10-mg/g increase in urinary albumin:creatinine ratio. For these outlined reasons, a white HIV-positive potential donor with no diabetes, no hypertension, no albuminuria, no history of smoking, and well-controlled infection may be viewed as a low-risk kidney donor candidate.
These findings and inferences reaffirm the observation that the risk of ESRD in HIV-positive individuals correlates directly with the quantity of replicating virus and, as We estimated the association of demographic and clinical characteristics with risk of ESRD separately for each cohort partly because the effects of age, black race, hypertension, and eGFR varied significantly by cohort (p < 0.05 for interaction terms with HIV status in a joint model in which viral load was coded as suppressed [i.e. 400 counts/mL], CD4 + count as 1000 cells/lL, and history of AIDS as "no" in the HIV-negative cohort). Also, because the entire HIV-positive cohort has no data on urinary albumin:creatinine ratio and >50% of the cohort has missing values for systolic blood pressure, we excluded these variables from the joint model (NA, not available in the HIV-positive cohort; not applicable to the HIV-negative cohort). 2 An inverse association was observed between age and risk of ESRD in both the HIV-positive and HIV-negative cohorts; however, this effect was not observed among those <50 years in the HIV-negative cohort (p < 0.001 for interaction between HIV status and age <50 years; however, p = 0.4 for interaction HIV status and age >50 years). 3 Black individuals had an increased risk of ESRD compared with white individuals; however, this increase in risk was significantly higher (>2-fold higher) in the HIV-positive cohort compared with the HIV-negative cohort (p = 0.03 for interaction). 4 Hypertension was associated with the risk of ESRD only in the HIV-positive cohort; however, the HIV-positive cohort model did not account for urinary albumin-to-creatinine ratio and systolic blood pressure. When albumin-to-creatinine ratio and systolic blood pressure were excluded from the HIV-negative cohort model, hypertension was associated with the risk of ESRD (HR 2.0; 95% CI: 1.2-2.8; p = 0.004). 5 An inverse association was observed between eGFR and risk of ESRD in both the HIV-positive and HIV-negative cohorts; however, this effect was not observed among those with eGFR >90 years in the HIV-negative cohort (p = 0.004 for interaction between those with eGFR >90 mL/min/1.73 m 2 in the HIV-positive versus the HIV-negative cohort; however, p = 0.4 for interaction between those with eGFR <90 years in the HIV-positive versus the HIV-negative cohort). such, that the use of ART may reduce this risk substantially (14, 19, 29) . While our finding of a 3.2-fold higher risk of ESRD in black compared with white HIV-negative individuals is consistent with well-established literature (30, 31) , our finding of a substantially stronger risk association (6.9-fold higher) of ESRD in black compared with white HIV-positive individuals is consistent with more recent and emerging literature (14, 15, 19, 32) . In this literature, there is compelling evidence that high-risk APOL1 haplotypes-found in individuals with African ancestrymight interact biologically with HIV infection (33) . According to studies of renal biopsy reports, HIV-positive individuals with high-risk APOL1 haplotypes have a much higher risk of developing the collapsing variant of focal segmental glomerulosclerosis and, as such, a much higher likelihood of rapid progression to ESRD (15) .
Data on APOL1 haplotypes were not available to us for this study, limiting the inferences we may make. While approximately 13% of African Americans in the general population have two high-risk APOL1 alleles, this prevalence estimate may not be generalizable to a population of kidney donor candidates and, as such, the diagnostic yield from genotyping HIV-positive potential donors remains unknown. But our findings support the view that risk of ESRD is best understood in terms of a number of risk factors that a given individual harbors, because the risk of ESRD varies by orders of magnitude among black individuals (8-100+ events per 10 000 in our study). It is plausible, for instance, that an individual with two highrisk APOL1 alleles may not develop progressive renal disease in the absence of other "hits," including diabetes, hypertension, cigarette smoking, uncontrolled HIV infection, HCV coinfection, and possibly other genetic risks (34) .
A second limitation of our study was that we were not able to adjust for as many baseline risk factors in the HIVpositive cohort as in the HIV-negative cohort, including urinary albumin:creatinine ratio and SBP. This may have limited our ability to stratify risk in the HIV-positive population and we may have overestimated the risk increase associated with HIV in the low-risk HIV-positive scenarios we describe. That said, in all low-risk HIV-positive scenarios we describe, participants had been using an ART regimen including older formulations of TDF for 1 year; those using TDF are likely to have been clinically screened and closely monitored for renal disease (urinalysis for albuminuria). For these reasons, it is plausible that in the low-risk scenarios we describe, the urine albumin:creatinine ratio was similar to that in comparable base-case scenarios in the HIV-negative cohort. In the future, individuals may switch to newer formulations of tenofovir (tenofovir alafenamide) that are safer for the kidneys than TDF (35). All HIV-positive scenarios specify the following characteristics: male sex, 1 year of ART use (including tenofovir), suppressed virus (<400 copies/mL), CD4 + count >500 cells/lL no diabetes, and no HCV coinfection; all HIV-negative scenarios specify the following characteristics: male sex, albumin:creatinine ratio 4 mg/g, SBP 120, no diabetes, and no HCV coinfection. Because these are hypothetical scenarios of potential HIV-positive donors, they do not include absolute contraindications to live kidney donation (presence of diabetes mellitus and HCV coinfection); however, two scenarios include a relative contraindication to live kidney donation (hypertension). 2 Per 10 000 at risk. 3 Expected eGFR by age and race for all scenarios except the values in bold (these are lower than expected for age/sex but meet eligibility criteria for kidney donation). The expected eGFR for each age varied significantly by race after accounting for sex, diabetes, hypertension, urinary albumin:creatinine ratio, SBP, BMI, and history of smoking. The magnitude of the difference between white and black individuals (approximately 10 mL/min/1.73 m Continuous and long-term health care may, as such, be a crucial factor in the long-term health of HIV-positive kidney donors. By extension, longitudinal data on use of ART, HIV viral load, and CD4 count may indicate an association between good adherence to ART, adequate viral control, and the best clinical outcomes. In this analysis, we did not adjust for these longitudinal variables because they are drawn from a time after the hypothetical "decision to donate"; however, donors should be informed about the potential benefits of regular postdonation care with the caveat that the association between postdonation healthcare and risk of ESRD remains unknown for both HIV-positive and HIV-negative populations. Granted, our findings suggest that individuals with well-controlled infection at baseline subsequently had, on average, a low risk of ESRD.
While the association between baseline hypertension and risk of ESRD was observed only in the HIV-positive cohort, this is most likely because in the HIV-positive cohort model we did not adjust for both urine albumin: creatinine ratio and BP (markers of glomerular disease and secondary hypertension) (36) (37) (38) . When both these variables were excluded from the HIV-negative cohort model, an association was observed between hypertension and risk of ESRD in a magnitude comparable to that observed in the HIV-positive cohort. Also, although we were able to adjust for BMI, a known risk factor for ESRD (39, 40) , in our exploratory analyses BMI was not significantly associated with ESRD in the HIV-positive cohort, so we did not include it in the final model. However, this might merely reflect the limited follow-up duration of our study.
Because we report 9-year cumulative incidence estimates, a third limitation of our study was the short duration of follow-up. Ideally, the HIV-positive potential donor would wish to know the magnitude of the additional lifetime risk of ESRD associated with donation. To obtain this estimate, we would need data on the projected lifetime risk of ESRD for HIV-positive potential donors in the absence of donation as well as data on the projected lifetime risk of ESRD for HIV-positive individuals in the event of donation; however, these data do not exist. Data from HIV-negative individuals suggest that donation is associated with a 4-to 11-fold increase in risk of ESRD (depending on race and sex), but the generalizability of these estimates to HIV-positive donors remains unknown (9, 10, 12) . That said, in this study we provide the first description, to the best of our knowledge, of the risk of ESRD among highly select HIV-positive individuals who may be considered for live donor nephrectomy. In this selected population, the 9-year adjusted risk was lowest for older HIVpositive individuals and highest for the young. This inverse association, which we have previously reported (19) , might reflect selective survival of healthier individuals; older age might represent a better risk profile and slower kidney disease progression in a manner that we were not able to characterize using the data available to us.
Our study also had several strengths worth considering. As a representative study of all HIV-positive individuals in care in North America (23, 24) , the inferences we make are generalizable to the US population of HIV-positive potential donors. Because we compared the risk of ESRD in HIV-positive potential donors with the risk in a representative population of HIV-negative potential donors in the United States (26), we were able to quantify the risk increase associated with HIV in potential donors. Also, our analytic approach allowed us to explore a wide range of scenarios that may guide decisionmaking in the unprecedented clinical setting ushered in by the recent passage of the Human Immunodeficiency Virus Organ Policy Equity Act of 2013. We have demonstrated biological gradients of risk based on renal function, viral load, CD4
+ count, and various other clinical characteristics. Thus, the clinician and HIV-positive potential donor may make decisions based on a combination of health characteristics of the prospective donor. Finally, we used validated and comparable methods to ascertain ESRD in both the HIV-positive and HIV-negative populations; thus, our findings are unlikely to be explained by differential ascertainment of the study outcome between the cohorts.
In conclusion, the carefully selected HIV-positive donor may face a real but acceptable additional risk of ESRD. Whether careful selection of black HIV-positive donors should entail genotyping for the high-risk APOL1 haplotypes is an important issue to explore in follow-up studies. 
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